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Background
Left ventricular assist devices (LVAD) are an increasingly used therapy for patients
with advanced heart failure. Arrhythmias are common complications following
LVAD implantation requiring admission, initiation, and escalation of medical
therapy. Despite their frequent use in the treatment of arrhythmias, little has been
reported regarding electrocardiographic changes, antiarrhythmic utilization, and
outcomes post-LVAD.
Methods
A total of 309 patients who received a LVAD underwent retrospective chart review
pre- and post-LVAD. Kaplan-Meier curves were calculated and compared using
the log-rank test. Cox regression model was used for univariate analysis and those
with a p<0.15 were included in multivariate analysis to evaluate for overall survival.
Results
There was a significant reduction in both the QRS interval (p=0.0001) and QTc
interval (p=0.0074) following LVAD implantation. Ventricular tachycardia is
common following LVAD implant at 31.1%. Amiodarone use was frequent prior to
LVAD (52.1%) and on discharge (68.6%). Amiodarone use (p=0.019, HR 1.7, 95%
CI 1.1-2.6), age at implant (p<0.001), creatinine (p=0.004), albumin (p=0.02), redcell distribution width (p=0.047), and prior median sternotomy (p<0.0001), were
associated with increased mortality. On multivariate analysis, only albumin
(p=0.013) and prior median sternotomy (p<0.001) remained statistically significant.
There was no significant difference in post-operative duration of intubation,
number of readmissions, or length of stay base on amiodarone utilization.
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Conclusions
Amiodarone is a commonly used antiarrhythmic in advanced heart failure and its
use prior to LVAD implantation may increase the risk of long-term mortality. The
amiodarone efficacy needs to be weighed against its long-term side effects and
implant on clinical outcomes.
Keywords: LVAD, antiarrhythmic, amiodarone, electrocardiography

Introduction
While treatments for heart failure have improved over the last two decades, the
number of patients with advanced heart failure who are or become refractory to
standard medical therapy continues to increase. Heart transplantation alone is not
possible for a large proportion of this increasing population of patients, due to an
overall plateau in the number of organs available for transplantation worldwide as
well as patient-specific factors making them poor candidates for heart
transplantation. With the continued development and improvement in left
ventricular assist device (LVAD) design, along with decreased morbidity and
mortality post-implantation, the incidence of new device implantations not only as
bridge to transplantation (BTT), but also as destination therapy (DT) has
significantly increased over the last 15 years.1 Arrhythmias, especially ventricular
arrhythmias, are a common post-LVAD complication, with an incidence ranging
from 22-59% and are frequently better tolerated in LVAD patients due to their
ability to maintain cardiac output when perturbations in heart rate and ventricular
synchrony are present.2, 3
Appropriate treatment of arrhythmias after LVAD implantation havs not been
completely defined and have only been reported in a couple of small, retrospective
studies.4, 5 While antiarrhythmic medications are frequently used to treat both atrial
and ventricular arrhythmias in LVAD patients, the use of these agents and the
outcomes associated with their used have not been adequately described. The
purpose of this study was to determine common rhythms/arrhythmias and
electrocardiographic (ECG) changes related to LVAD implantation as well as
antiarrhythmic utilization to treat these arrhythmias and how these impact
outcomes following implantation.

Methods
Study Population
We conducted a retrospective chart review of 309 patients who underwent LVAD
implantation as BTT or DT at The University of Nebraska Medical Center between
July 2004 and October 2017. This involved a full review of the patient's electronic
health records (EHR), including physician progress notes, nursing notes, telemetry
records, and implantable cardioverter defibrillator (ICD) interrogations, evaluating
for documented evidence of atrial or ventricular arrhythmias as well as patient's
medication administration records to document prescribing of antiarrhythmic
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medications. Records were reviewed from the time of first preoperative evaluation
by our cardiology or cardiothoracic surgery team and followed postoperatively until
death, heart transplant, or completion of data collection on November 27th, 2017.
The study was approved by the institutional review board at our institution.
Clinical Variables
We obtained demographic and clinical variables on patients undergoing LVAD
implantation via review of the EHR. These variables included age, gender, left
ventricular ejection fraction (LVEF), left ventricular internal diameter end diastole
(LVIDd), ICD status, routine laboratory values (e.g. potassium, creatinine, albumin,
etc.), antiarrhythmic therapy and other drug therapy pre- and post-LVAD
implantation, and other pertinent medical history (e.g. presence of arrhythmias,
pre-implantation comorbidities, etc.).
Ventricular tachycardia (VT) was defined as sustained or non-sustained VT
(NSVT) with symptoms requiring antiarrhythmic therapy. Preoperative VT and
atrial fibrillation (afib) were defined as documentation within clinical notes,
telemetry records, or ECG of VT or afib prior to LVAD implantation. Postoperative
VT or afib were defined as documented VT or afib within clinical notes, telemetry
records, or ECG following LVAD implantation.
Pre- and post-LVAD ECG intervals (PR, QRS, QT, and QTc) and rhythms were
obtained via review of each ECG documented in the patient's EHR. Both
ventricular-paced and non-paced rhythms and intervals were documented for
comparison between pre- and post-implantation periods.
Statistical Analysis
Descriptive statistics included counts and percentages for categorical data and
means and standard deviations for continuous data. The independent sample ttest was used to compare continuous measures between groups. Overall survival
(OAS) was defined as the time from implant to time of death from any cause.
Patients who underwent heart transplantation were censored at the time of
transplant and patients who underwent LVAD explantation or defunctionalization
were censored at the time of this surgery. The OAS curve was calculated using the
Kaplan-Meier method and compared using the log-rank test. Confidence interval
for estimate of time-to-event distribution was calculated using Greenwood's
formula. The Cox regression model for censored data was used to examine patient
characteristics of OAS in a univariate analysis. Factors significant on univariate
analysis (p < 0.15) were included in the multivariate analysis. For secondary
outcomes, Fisher's exact test was used to compare intubation at 24 hours
between groups and the Mann-Whitney test was used to compare the median LOS
and hospital readmissions between groups. A p-value of <0.05 was considered
statistically significant.

Results
Our study population included 309 patients, 240 (77.7%) were males and the
mean age was 56.7 (12.9) years. Destination therapy was the implant strategy for

The VAD Journal: https://doi.org/10.13023/vad.2018.08

Page 3 of 15

The VAD Journal: The journal of mechanical assisted circulation and heart failure

187 (60.5%) patients and 163 (52.7%) had ischemic cardiomyopathy. The mean
left ventricular ejection fraction (LVEF) was 17.9% (8.9) and mean left ventricular
internal dimension in diastole (LVIDd) was 64.7 mm (9.1). Patients on amiodarone
prior to LVAD implantation tended to be older (59.2 vs 54 years, p<0.0001), more
likely female (25.8% vs 18.7%, p=0.04), have a history of chronic obstructive
pulmonary disease (27% vs 16.7%), have a higher creatinine (1.37 vs 1.25,
p=0.01), lower albumin (3.27 vs 3.31, p=0.04), and have higher prevalence of
ventricular tachycardia (62.9% vs 24.7%, p<0.0001) and atrial fibrillation (71.7% vs
38%, p<0.0001). Full pre-LVAD clinical characteristics are shown in Table 1.
Table 1. Pre-LVAD Implantation Patient Characteristics and Hemodynamics
Characteristic

Age, y (SD)
Female Sex, N (%)
BTT Implant Strategy, N (%)
Pre-LVAD BMI, kg/m2 (SD)
Ischemic Cardiomyopathy, N (%)
Baseline LVEF, % (SD)
Baseline LVIDd, mm (SD)
INTERMACS Profile at Implantation
1
2
3
4
5-7
Comorbidities
Hypertension, N (%)
Diabetes Mellitus, N (%)
Obstructive Sleep Apnea, N (%)
COPD, N (%)
Chronic Kidney Disease, N (%)
Prior Median Sternotomy, N (%)
Ventricular Tachycardia, N (%)
Atrial Fibrillation, N (%)
Lab Values
Hemoglobin, g/dL (SD)
Creatinine, mg/dL (SD)
Albumin, g/dL (SD)
RDW, % (SD)
Pre-LVAD Hemodynamics
Right Atrial Pressure, mmHg (SD)
Pulmonary Artery Saturation, % (SD)
Wedge Pressure, mmHg (SD)
Fick Cardiac Index, L/min/m2 (SD)

Total
population,
N=309
56.7 (12.9)
69 (22.3)
187 (60.5)
30.1 (6.6)
163 (52.8)
17.9 (8.9)
64.7 (9.1)

Pre-LVAD
Amiodarone,
N=159
59.2 (11.7)
41 (25.8)
92 (57.9)
29.69 (5.4)
88 (55.3)
19.5 (10.3)
64.1 (9)

No Pre-LVAD
Amiodarone, N=
150
54.0 (13.7)
28 (18.7)
96 (64)
30.40 (7.9)
74 (49.3)
17 (8.4)
65.1 (9.4)

p-value

<0.0001
0.04
0.29
0.99
0.54
0.034
0.25

63 (20)
83 (27)
99 (32)
62 (20)
2 (1)

31
41
50
36
0

32
42
49
26
2

0.69
0.66
0.82
0.24
0.14

186 (60.2)
123 (39.8)
92 (29.8)
68 (22)
99 (32)
100 (32)
137 (44.3)
171 (55.3)

102 (64.2)
66 (41.5)
52 (32.7)
43 (27)
57 (35.8)
53 (33.3)
100 (62.9)
114 (71.7)

83 (55.3)
58 (38.7)
40 (26.7)
25 (16.7)
42 (28)
47 (31.3)
37 (24.7)
57 (38)

0.20
0.73
0.27
0.039
0.18
0.72
<0.0001
<0.0001

11.8 (2.0)
1.3 (0.4)
3.3 (0.6)
15.9 (2.5)

11.7 (2)
1.37 (0.45)
3.27 (0.55)
15.9 (2.4)

12 (2)
1.25 (0.41)
3.41 (0.55)
15.8 (2.7)

0.12
0.01
0.04
0.39

12.5 (6.3)
53 (10.3)
24 (8.9)
2 (0.5)

12.8 (6.4)
53.2 (10.7)
23.7 (9.1)
2.09 (0.6)

12.3 (6.2)
52.7 (10)
24.4 (8.7)
1.97 (0.5)

0.56
0.65
0.32
0.057

Y= year; DT =destination therapy; BMI = body mass index; SD = standard deviation; BSA = body
surface area; LVEF = left ventricular ejection fraction; LVIDd= left ventricular internal dimension in
diastole; RDW = red blood cell distribution width; TSH= thyroid stimulating hormone; ICD=
implantable cardioverter defibrillator; CRT-D= cardiac resynchronization therapy-defibrillator
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Of the 290 patients who survived to discharge, 143 (49.3%) patients had CRT-D in
place, with no new patients receiving or being upgraded to CRT-D following LVAD
implantation. A total of 135 (46.6%) patients had an ICD in place at the time of
discharge compared to 83 (28.6%) patients at the time of index admission. Nine
patients were discharged from the hospital without an ICD in place. ECGs were
evaluated both pre- and post-LVAD implantation. A total of 76 patients had a nonventricularly paced ECG within 1 month prior to LVAD implantation and a nonventricularly paced ECG 3 or more months following LVAD implantation for
comparison of intervals pre- and post-LVAD (Table 2).
Table 2. Comparison of Non-Ventricular Paced ECG Intervals Pre- and PostLVAD Implantation
ECG Interval
PR
QRS
QT
QTc (Bazett)

Average Pre-LVAD
Duration, ms (SD)
174.3
115.2
393.9
485.6

Average Post-LVAD
Duration, ms (SD)
169.5
102.9
406.4
466.8

P value (95% CI)
0.23 (-3.9-16.0)
0.0001 (6.6-17.4)
0.14 (-29.2-4.2)
0.0074 (5.2-32.5)

Of the 309 patients in our study, 137 (44.3%) patients had documented NSVT or
sustained VT prior to undergoing LVAD implantation. Thirty-nine (12.6%) patients
were admitted to the hospital for their index admission because of VT or had VT
during their admission, but prior to undergoing LVAD implantation. The most
common pre- and post-LVAD rhythm was a ventricular-paced rhythm (Vpaced)
with 118 (38.2%) patients having this as their primary rhythm prior to implantation
and 111 (35.9%) having this as their primary rhythm post-implantation (Table 3).
Table 3. Most Common Heart Rhythms Pre- and Post-LVAD Implantation
Rhythm
Ventricular Paced
Normal Sinus Rhythm
Sinus Tachycardia
Afib/Aflutter
Unknown Rhythm
Atrial Paced
Sinus Bradycardia

Pre-LVAD, N (%)
118 (38.1)
106 (34.3)
48 (15.5)
17 (5.5)
8 (2.6)
7 (2.3)
5 (1.6)

Post-LVAD, N (%)
111 (36.0)
103 (33.3)
33 (10.7)
21 (6.8)
37 (12.0)
4 (1.3)
0 (0.0)

Atrial fibrillation or atrial flutter were present in 171 (55.3%) patients prior to LVAD
implantation and 120 (38.8%) patients post-LVAD, but these were the primary
rhythm in only 17 (5.5%) patients pre-LVAD and 21 (6.8%) patients post-LVAD.
A total of 98 (31.7%) patients had a ventricular arrhythmia following LVAD
implantation. Ninety-three (94.9%) had VT only, 2 (2%) patients had VF only, and
3 (3%) patients had both VT and VF following implantation. Of the 98 patients who
had a ventricular arrhythmia post-LVAD, 48 (49%) patients had a history of
ventricular arrhythmia pre-LVAD, while the other 50 (51%) patients had a
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ventricular arrhythmia only after LVAD. While 12 (3.9%) patients underwent VT
ablation prior to LVAD implantation, only 1 (0.3%) patient had a VT ablation in the
post-implantation period. Frequent post-implantation VT and limited VT ablation
led to frequent prescribing of antiarrhythmics post-LVAD, with 225 (72.8%)
patients being prescribed at least one antiarrhythmic in the post-implantation
period. Only 24 (7.8%) patients were on multiple antiarrhythmic concurrently
following LVAD implantation. A total of 161 (52.1%) patients were on amiodarone
within 2 years prior to LVAD implantation and 158 (51.4%) patients who survived
to discharge were continued on amiodarone at the time of their dismissal. Drug
utilization frequencies pre- and post-implantation are listed in Table 4.
Table 4. Drug Utilization Pre- and Post-LVAD Implantation
Medication
On beta blocker at time of LVAD admission, N (%)
On amiodarone within 2 years prior to LVAD, N (%)
Discharged on beta blocker post-LVAD, N (%)
Discharged on digoxin post-LVAD, N (%)
Discharged on amiodarone post-LVAD, N (%)
On beta blocker 3 months post-LVAD, N (%)
Antiarrhythmic therapy post-LVAD, N (%)
Amiodarone use at any point post-LVAD, N (%)
Post-LVAD Mexiletine, N (%)
Post-LVAD Sotalol, N (%)
Post-LVAD Dofetilide, N (%)
Post-LVAD Quinidine, N (%)

Utilization
225 (72.8)
159 (51.4)
76 (27.7)
110 (40.1)
158 (57.7)
89 (34.9)
225 (72.8)
212 (68.6)
18 (5.8)
12 (3.9)
5 (1.6)
2 (0.6)

On univariate analysis, amiodarone was associated with increased mortality, with
a hazard ratio of 1.699 (P=0.0193, CI 1.090-2.648). The Kaplan-Meier survival
curve is displayed in Figure 1. Other variables associated with increased mortality
include age at implant (p=0.0006), creatinine (p=0.0042), albumin (p=0.022), RDW
(p=0.0469), and prior median sternotomy (p<0.0001) (Table 5).
Table 5. Univariate Analysis of Pre-LVAD Variables and Their Impact On
Survival

Variable
Pre-LVAD amiodarone
Age at Implant
BMI at Implant
Pre-LVAD Creatinine
Pre-LVAD Albumin
Pre-LVAD RDW
Pre-LVAD COPD
Prior Pre-LVAD sternotomy

The VAD Journal: https://doi.org/10.13023/vad.2018.08

Hazard
Ratio
1.699
1.04
0.99
1.97
0.63
1.08
1.13
2.30

P-Value
0.019
0.0006
0.68
0.004
0.022
0.047
0.63
<0.0001

95% Confidence
Interval
1.09-2.65
1.02-1.06
0.96-1.03
1.24-3.14
0.43-0.94
1.001-1.17
0.69-1.84
1.57-3.73
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Figure 1. Kaplan-Meier survival curve showing worse post-implantation
survival in patients who were on amiodarone prior to LVAD compared to
those who were not on Amiodarone
On multivariate analysis, only albumin (p=0.03) and prior median sternotomy
(p<0.001) remained independent predictors of survival (Table 6). The use of
amiodarone prior to LVAD implantation did not have an impact on duration of
intubation following LVAD placement (p=0.43), length of stay following LVAD
implantation (p=0.10), or number of readmissions (p=0.57).
Table 6. Multivariate Analysis of Pre-LVAD Variables and Their Impact on
Survival
Variable
Pre-LVAD amiodarone use
Age at Implant
Pre-LVAD Creatinine
Pre-LVAD Albumin
Pre-LVAD RDW
Prior Pre-LVAD sternotomy

The VAD Journal: https://doi.org/10.13023/vad.2018.08

Hazard
Ratio
1.5
1.0
1.5
0.6
1.0
2.3

P-Value
0.09
0.16
0.11
0.03
0.35
<0.001

95% Confidence
Interval
0.94-2.38
0.99-1.04
0.91-2.57
0.42-0.96
0.96-1.1
1.41-3.62
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Discussion
This single center, retrospective study showed that patients with a history of
amiodarone use within two years of LVAD implantation were at increased risk of
post-operative mortality, as were older patients, those with prior median
sternotomies, low albumin, and high creatinine and RDW. On multivariate analysis,
only albumin and prior median sternotomy remained independent predictors of
mortality. This study also showed that mechanical unloading of the heart leads to a
significant reduction in the QRS and QTc intervals. We found that ventricular
tachycardia is common in end-stage heart failure, both pre- and post-LVAD
implantation and amiodarone is the most commonly used antiarrhythmic used to
treat arrhythmias before and after LVAD implantation.
ECGs were evaluated both pre- and post-LVAD implantation for rhythm and
interval durations. A total of 76 patients had non-ventricularly paced ECGs both
pre- and post-LVAD implantation available for comparison. We found a statistically
significant decrease in QRS duration (p=0.0001) as well as a significant decrease
in the QTc interval (p=0.0074) from pre- to post-implantation. Harding and
colleagues previously looked at changes in ECG intervals pre- and post-LVAD and
found a significant decrease in the QRS immediately post-implant (within 6 hours),
but this was not sustained more than a week post-LVAD.6 It has been
hypothesized that since changes in conduction velocity after cardiac distension
have not been identified, possible decreases in cardiac dimensions post-LVAD
lead to an overall decrease in conduction distance and thus a decrease in QRS
duration. This same group has also noted a significant increase in QT and QTc
intervals in the immediate post-implantation period followed by a significant
decrease in these intervals more than 1-week post-implantation.7, 8 While we did
not evaluate ECGs in the immediate post-implantation period, we did identify a
significant decrease in the QTc interval when evaluating a more delayed effect of
mechanical unloading on ECG characteristics. Action potential prolongation has
previously been shown to be a common abnormality in failing hearts and it has
been hypothesized that mechanical unloading of failing hearts reverses this
characteristic resulting in decreased action potential durations and thus, shorter
QTc intervals. 9
The primary rhythm identified on ECG and telemetry review in our study was Vpaced, both in the pre-LVAD (38.1%) and post-LVAD (36%) time periods. Martinez
and colleagues have previously shown a similar prevalence of V-paced rhythm in
their pre-implantation population at 40%, but the percentage of patients primarily
V-paced following implantation increased to 79% in their study. Normal sinus
rhythm and sinus tachycardia were the next two most common rhythms both preand post-implantation. There was a low number of patients without ECGs obtained
in the pre-LVAD period (2.8%) and significantly higher in the post-implantation
period (12%). Martinez and colleagues have emphasized the importance of
obtaining an ECG in every patient in the post-implantation period to establish a
new baseline.10 While most of the rhythm monitoring in the post-implantation
period is done via ICD interrogation, ECGs are still clinically useful for monitoring
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of the QT/QTc duration, especially in patients receiving antiarrhythmic therapy and
potentially identifying patients at risk for ventricular arrhythmias.
Our study showed that 31.3% of patients had VT following LVAD implantation,
which is in line with previous studies that have found that VT occurred anywhere
from 22-59% following LVAD implantation.11, 12 We also found that 44.3% of
patients had at least one episode of VT prior to undergoing LVAD implantation with
12.6% of patients having an episode of VT leading to index admission or during
the in-hospital evaluation prior to implantation. Afib was a problem for 55.3% of
patients prior to LVAD, but only 38.8% of patients continued to have issues with
afib following implantation. A previous study by Enriquez and colleagues showed a
slightly higher incidence of afib post-LVAD at 51.9%.13 They also found that
persistent afib was an independent predictor of death and hospitalization for heart
failure. While previous studies have shown that ventricular arrhythmias tend to
occur within the first week to month following LVAD-implantation,4, 14 timing of
ventricular arrhythmias was not evaluated in our study.
We found that 49% of patients had CRT in place prior to undergoing LVAD
implantation and this did not change following implantation. While only 26.9% of
patients had a single-chamber ICD in place prior to LVAD implantation, 52 new
devices were implanted in the post-implantation period. In our study, 75.7% of
patients had an ICD in place (whether biventricular or single chamber) at the time
of LVAD implantation. Previous studies have had significant variability in the
number of patients with ICDs in place prior to LVAD implantation, ranging
anywhere from 18.8% and 31.1%, up to 75.5%.15-17 Our study is more in line with
data presented by Enriquez and colleagues, with 75.7% having an ICD in place at
the time of LVAD, likely indicating that our patients tend to have more chronic
heart failure with attempts at optimizing their medical and device therapy prior to
proceeding with LVAD and transplant evaluation.17
There was a total of nine patients who were discharged without an ICD in place.
The reasons for not placing an ICD in these patients varied and included: 1.) prior
ICD explantation due to infection, 2.) two with improvement in left ventricular
function or decrease in ectopy prior to discharge, 3.) electrophysiology study
showing no inducible VT, 4.) receipt of heart transplantation prior to initial
discharge, 5.) concern for hypotension with anesthesia and risk for neurologic
event, and 6.) three patients with unclear documentation as to why no ICD was
placed. To our knowledge, there are no studies investigating the use of
intracardiac EP studies in the post-LVAD population to assess low-risk patients for
inducible VT to help direct ICD placement. A recent meta-analysis of six
observational studies totaling 937 patients showed ICD use in LVAD patients was
associated with a significant reduction in mortality, but in a subgroup analysis of
361 patients with continuous flow LVADs, there was not a statistically significant
decrease in mortality following LVAD implantation with an ICD in place.18
Antiarrhythmic medications are frequently used to treat both atrial and ventricular
arrhythmias in advanced heart failure patients both before and after LVAD
implantation. We found that 72.8% of patients were on at least one antiarrhythmic
medication in the post-implantation period. Amiodarone was the most commonly
used antiarrhythmic, with 94% of the patients requiring antiarrhythmic therapy
The VAD Journal: https://doi.org/10.13023/vad.2018.08
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being on amiodarone. Amiodarone use was equally frequent in the pre-LVAD
period (52%) and in the post-LVAD period, with 51% of patients being discharged
from the hospital on amiodarone following LVAD implantation. Previous studies
have also shown that amiodarone is the most commonly used antiarrhythmic in the
post-LVAD setting, with 66.7-75% of antiarrhythmic utilization for VT being done
with amiodarone.11, 14 The utilization of beta-blockers at discharge and 3 months
following LVAD implantation is low in our institution (Table 4), historically due to
concern for increased risk of right ventricular failure. Wever-Pinzon and colleagues
recently showed that patients on a beta-blocker at 12 months following LVAD
implantation were more likely to experience cardiac recovery and small,
retrospective studies have shown it may improve post-implantation survival and
does not appear to increase the number of heart failure readmissions. 19-21
The side effects of long-term amiodarone use have been documented since the
early 1980s and primarily involve the thyroid gland, liver, lungs, skin, and cornea.22
Given amiodarone's frequent usage in patients undergoing heart transplant
evaluation because of increased incidence of ventricular arrhythmias, a few
studies over the last 20 years have looked at postoperative outcomes following
heart transplantation in patients who received amiodarone in the pre- and postoperative period. Chin et al published a retrospective review in 1999 of 106
consecutive heart transplants and found that patients who had received
amiodarone for more than 4 weeks pre-transplant had higher mortality at 1 year.23
Blomberg and colleagues found that patients who had received amiodarone within
3 months of heart transplant had decreased survival post-transplant, required
longer periods of postoperative ventilatory support, and were more likely to
experience bleeding complications.24 More recently, Cooper and colleagues
published a retrospective cohort analysis of 14,955 patients from the International
Society for Heart and Lung Transplantation registry that again found that patients
treated with amiodarone prior to heart transplant had higher 1-year mortality but
did not find increased risks of early graft failure, retransplantation, or
rehospitalizations.25 To our knowledge, there have not been prior reports looking at
amiodarone utilization prior to LVAD implantation and its impact on post-operative
outcomes.
Despite 137 patients having VT prior to LVAD implantation and 96 patients having
VT post-implantation, only 12 patients underwent VT ablation pre-LVAD and 1
patient post-LVAD at our institution. Per-LVAD and post-LVAD VT ablation have
previously been well described in several studies. Garan and colleagues looked at
224 patients who underwent LVAD placement and identified 7 patients who
underwent EP study and VT ablation following LVAD implantation.26 Multiple VTs
were identified and ablated, with 5 of the 7 patients having a significant reduction
in their VT following ablation.26 A larger study evaluated 611 patients who
underwent LVAD implantation over almost a 20-year period and identified 21
patients who underwent post-LVAD EP study. Of the 20 patients who had
inducible VT, 18 had acute ablative success with 7 patients having recurrent VT
and underwent a repeat procedure.27 Amiodarone use decreased in both studies
post-ablation with each study noting very few procedural complications and low
post-procedural morbidity and mortality. Intraoperative ablation has been
evaluated in a study of 5 patients who underwent peri-LVAD open chest hybrid
epicardial mapping and VT ablation with 3 of the 5 patients having acute
The VAD Journal: https://doi.org/10.13023/vad.2018.08
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procedural success and no arrhythmia related deaths in any of the patients over a
mean follow-up period of 363 ± 368 days.28
On a univariate analysis, we found that patients on amiodarone within two years
prior to LVAD implantation had an increased risk of mortality, with a HR of 1.7 and
p=0.019. We also found that pre-implantation albumin, creatinine, and RDW as
well as patient's age and history of prior median sternotomy predicted an
increased risk of mortality on univariate analysis. Our findings confirm prior studies
showing increased risk of mortality with lower albumin, higher RDW, worse renal
function, and increasing age at the time of implantation.29-34 Our findings of
increased risk of mortality in patients with a history of a previous sternotomy prior
to LVAD implantation conflict with a recent study published by Papathanasiou and
colleagues. In their study of 112 patients who underwent implantation with
HeartWare (HeartWare International Inc., Framingham, MA), they found no
difference in survival rate at 6 months (p=0.37) in patients who had a history of
prior median sternotomy at the time of LVAD implantation compared to those
without prior sternotomy.35 In our study, history of prior median sternotomy was the
strongest predictor of increased mortality (p<0.0001) and on multivariate analysis
remained an independent predictor of mortality (p=0.0007). Pre-LVAD albumin
(p=0.0302) was the only other independent predictor of increased mortality on
multivariate analysis, similar to findings previously described by Kato and
colleagues.
There are several limitations to our study. This is a single-center experience
involving both DT and BTT patients. Our analysis is retrospective in nature with a
limited patient population. In some cases, pre- and post-LVAD ECGs were not
available and prevented full evaluation of the entire patient population. Transition
to a new electronic health record during the study period may have created
difficulties in transfer of information between the systems as well as documentation
early on.
In summary, the present study shows a significant decrease in QRS and QTc
intervals post-LVAD implantation. Amiodarone was frequently used in both the preand post-LVAD setting to treat both atrial and ventricular arrhythmias. Amiodarone
use may increase post-LVAD mortality. Despite the incidence of VT both before
and after LVAD implantation, ablation was performed relatively infrequently in our
patient population. With numerous studies showing increased mortality following
heart transplant in patients who received pre-transplant amiodarone and our study
showing pre-LVAD amiodarone potentially being associated with worse survival on
univariate analysis, further studies need to be done investigating amiodarone
reduction strategies and if ablation for recurrent VT is a superior strategy in
patients undergoing transplant evaluation or with LVADs as bridge to transplant.
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